NUVALENT INC-A
NUVLNASDAQTrading Snapshot
- Day Range
- $307.47 – $313.40
- 52-Week Range
- $71.13 – $123.99
- Volume
- $2.33B
- Avg Volume
- $1.65B
- Shares Outstanding
- 73.7M
- Next Earnings
- Nov 20, 2026
Fundamentals Snapshot
- Annual Revenue
- $3.38B
- Last Q Revenue
- $769M
- P/E Ratio
- -20.5
- P/S Ratio
- 0.0x
- EPS (TTM)
- $-5.72
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +5.6%
Why Investors Own NUVL
- ✓High-growth profile — revenue up +22.0% YoY with expanding US Equity exposure.
- ✓Healthy economics — 36% gross margin and 20% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
NUVALENT INC-A
NUVL
StockOtter · stockotter.spaceAbout NUVALENT INC-A
Nuvalent, Inc. is a clinical-stage biopharmaceutical firm dedicated to pioneering novel therapeutic solutions for individuals battling cancer. The company's pipeline features two prominent drug candidates. One of these is NVL-520, a highly selective ROS1 inhibitor capable of penetrating the brain. This compound is specifically designed to target ROS1 fusions that possess the normal ROS1 kinase domain, and crucially, it retains activity against mutations known to confer resistance to both approved and experimental ROS1 inhibitors. NVL-520 is currently undergoing Phase I clinical evaluation. Nuvalent's second key asset is NVL-655, an ALK-selective inhibitor that also exhibits brain-penetrant properties. This therapy seeks to address significant limitations of earlier generations of ALK inhibitors (first-, second-, and third-generation), including the development of treatment resistance, central nervous system-related adverse effects, and brain metastases. NVL-655 is presently being assessed in Phase I/II clinical trials. The company was established in 2017 and is based in Cambridge, Massachusetts.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Ratings
ⓘLatest News & Updates
NUVALENT INC-A tops quarterly estimates as demand accelerates
Revenue grew double digits with management guiding above consensus; margins continued to expand.
Analysts lift NUVL price targets on improving margins
Several firms raised targets, citing stronger free cash flow and a healthier backlog.
NUVALENT INC-A announces new agreement to expand its footprint
The move broadens the company’s reach and could add incremental revenue over the next year.